Dr. Paulson Discusses Acquired Resistance to Immunotherapy

Kelly Paulson, MD
Published: Friday, Nov 17, 2017



Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

One of the biggest challenges in immunotherapy is resistance to treatment, says Paulson. Investigators are currently trying to develop next-generation immunotherapies to treat patients who initially responded to immunotherapy, but then recurred.
 


Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

One of the biggest challenges in immunotherapy is resistance to treatment, says Paulson. Investigators are currently trying to develop next-generation immunotherapies to treat patients who initially responded to immunotherapy, but then recurred.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x